Acar, Ali

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14411/7675
Name Variants
A., Ali
Acar, Ali
A.,Acar
A.,Ali
Ali, Acar
A., Acar
Acar,A.
Job Title
Profesör Doktor
Email Address
ali.acar@atilim.edu.tr
Main Affiliation
Basic Sciences
Status
Former Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
4
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
1
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
This researcher does not have a Scopus ID.
This researcher does not have a WoS ID.
Scholarly Output

4

Articles

4

Views / Downloads

22/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

6

Scopus Citation Count

5

Patents

0

Projects

0

WoS Citations per Publication

1.50

Scopus Citations per Publication

1.25

Open Access Source

2

Supervised Theses

0

JournalCount
Arab Journal of Gastroenterology1
Infectious diseases and clinical microbiology (Online)1
Journal of the American Podiatric Medical Association1
Klimik Dergisi/Klimik Journal1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

20231
Reset filters

Settings

Author: Azap, Alpay

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    Citation - WoS: 2
    The Impact of Vaccination Among Hospitalized Patients With the Diagnosis of Covid-19
    (Doc design informatics Co Ltd, 2023) Yıldız, Yeşim; Özger, Hasan Selçuk; Acar, Ali; Keskin, Ayşegül Seremet; Binay, Umut Devrim; Ünlü, Gülten; Diseases, The Adult Immunization Study Group Of The Turkish Society Of Clinical Microbiology And Infectious; Seremet-Keskin, Aysegul; Azap, Alpay; Senol, Esin; Bayındır, Yasar; Kaya, Safak; Saygideger, Yasemin; Mete, Ayşe Özlem
    Objective: We aimed to investigate the vaccination status and the risk factors for the in- tensive care unit (ICU) support need of the laboratory-confirmed breakthrough COVID-19 infection inpatients. Materials and Methods: This multi-center point-prevalence study was conducted on inpa- tients, divided into two groups as ‘fully’ and ‘partially’ vaccinated according to COVID-19 vaccination status. Results: Totally 516 patients were included in the study. The median age was 65 (55-77), and 53.5% (n=276) of the patients were male. Hypertension (41.9%, n=216), diabetes mel- litus (DM) (31.8%, n=164), and coronary artery disease (CAD) (16.3%, n=84) were the pre- dominant comorbidities. Patients were divided into two groups ICU (n=196) and non-ICU (n=301). Hypertension (p=0.026), DM (p=0.048), and congestive heart failure (CHF) (p=0.005) were significantly higher in ICU patients and the median age was younger among non-ICU patients (p=0.033). Of patients, 16.9% (n=87) were fully vaccinated, and this group’s need for ICU support was statistically significantly lower (p=0.021). Conclusion: We conclude that older age, hypertension, DM, CHF, and being partially vacci- nated were associated with the need for ICU support. Therefore, all countries should con- tinuously monitor post-vaccination breakthrough COVID-19 infections to determine the national booster vaccine administration approach that will provide vulnerable individuals the highest protection.